PE-backed Gemini taps Perry as COO

Gemini Bioproducts, which is backed by BelHealth Investment Partners LLC, has named Robert Perry as chief operating officer. Perry is the ex-senior director at Atara Biotherapeutics. Gemini is a provider of cell culture reagents.

PRESS RELEASE

WEST SACRAMENTO, CA, November 1, 2019 – Gemini Bioproducts, LLC (“Gemini”), a leading supplier of cell culture reagents and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, announced the appointment of Robert Perry as Chief Operating Officer.

Robert Perry has over thirty years of life sciences industry experience in biotechnology and cell therapy companies. His career has spanned multi-functional roles including pilot and full-scale manufacturing, quality, materials science and engineering, and facilities design and build. Most recently, Mr. Perry was a Senior Director at Atara Biotherapeutics (NASDAQ: ATRA), where he established and oversaw the company’s Materials Science program through qualification of its key raw materials suppliers. Prior to that, Mr. Perry was also a Senior Director of CMC Manufacturing, where he led the end to end buildout of Atara’s 120,000 sq. ft. manufacturing facility in Thousand Oaks, CA. Mr. Perry’s previous experience includes key roles at Athersys, Inc. as VP of Manufacturing and Biocircuits Corporation. He was also an Adjunct Assistant Professor at Case Western Reserve University School of Medicine. Mr. Perry began his career at Becton Dickinson.

Dale Gordon, CEO of Gemini, stated “I am delighted to welcome Rob to the Gemini executive leadership team. Rob’s deep manufacturing and operational expertise will be instrumental to Gemini’s continued focus on compliance and quality as we continue to grow as a customer-centric life sciences tools platform. Furthermore, Rob’s recent experience at Atara is very germane to several of Gemini’s near-term strategic endeavors, including the buildout of our new GMP facility, which we expect to complete in early 2020.”

Rob Perry added, “I look forward to joining Dale and the team at Gemini in this exciting role. Gemini is a unique bioprocessing solutions platform that has evolved to be a trusted partner to many of its biotech and academic customers in a fast growing and constantly developing landscape around new therapeutic developments such as CAR-T. I am excited to work with Gemini to scale the Company to best serve our customers’ evolving needs.”

About Gemini Bio-Products
Founded in 1985, Gemini is a leading manufacturer and supplier of cell culture media, sera, and other reagents to the scientific community across academic research and the biotechnology, cell and gene therapy, and biopharma industries. Service offerings include fill & finish and custom media development. Today, a national sales force and an international distribution network serves cell culture laboratories worldwide.

About BelHealth Investment Partners
BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm invests across three core healthcare segments: Services, Products and Distribution. BelHealth is investing from its current $350 million fund.